Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhibitor development in correlation to factor VIII genotypes.

J Oldenburg1, O El-Maarri, R Schwaab

  • 1Institute of Transfusion Medicine and Immune Haematology of the DRK Blood Donor Service Hessen, Frankfurt, Germany. joldenburg@bsd-hessen.de

Haemophilia : the Official Journal of the World Federation of Hemophilia
|April 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Leitlinie der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) zur Struktur- und Prozessqualität von Hämophilie-Zentren.

Hamostaseologie·2024
Same author

Fibrinogen Bonn (p. Arg510Cys) in the Aα-Chain Is Associated with High Risk of Venous Thrombosis.

Hamostaseologie·2023
Same author

Experiences in Routine Genetic Analysis of Hereditary Hemorrhagic, Thrombotic, and Platelet Disorders.

Hamostaseologie·2022
Same author

Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.

ESMO open·2021
Same journal

Exploratory Claims-Based Assessment of Diagnosed and Potentially Undiagnosed von Willebrand Disease in Japan.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Use of an Oral Health-Related Quality of Life Instrument to Measure Unmet Dental Care Needs in Adults With Inherited Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Factors for Predicting Synovial Hypertrophy in Early Haemophilic Arthropathy on Prophylaxis: A Cross-Sectional Study of Patient- and Joint-Level Analyses Using Musculoskeletal Ultrasound.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Utilisation and Perceived Value of Genetic Counsellors Within US Haemophilia Treatment Centres.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Correction to "Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry".

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Monitoring of Coagulation Potential of Efanesoctocog Alfa in Haemophilia A: Insights From Conventional and Global Hemostasis Assays.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Inhibitors against factor VIII (FVIII) complicate severe hemophilia A treatment. FVIII gene mutation type significantly impacts inhibitor risk and epitope specificity, especially in severe cases.

Area of Science:

  • Immunology
  • Genetics
  • Hematology

Background:

  • Alloantibodies (inhibitors) to factor VIII (FVIII) affect 20-30% of severe hemophilia A patients, impeding FVIII therapy.
  • Genetic factors, including FVIII gene mutations and immune response genes, influence inhibitor development.

Purpose of the Study:

  • To investigate the impact of FVIII gene mutation type on inhibitor formation and characteristics in severe hemophilia A.
  • To explore the relationship between mutation site, epitope specificity, and inhibitor titer.

Main Methods:

  • Analysis of genetic factors influencing inhibitor development in hemophilia A patients.
  • Identification of FVIII epitopes targeted by antibodies.
  • Correlation of FVIII gene mutation types with inhibitor prevalence and characteristics.

Related Experiment Videos

Main Results:

  • Severe FVIII gene defects (e.g., large deletions, nonsense mutations) confer a 7-10 times higher inhibitor prevalence than milder defects (e.g., missense mutations).
  • At least 10 mutation classes show differing risks of inhibitor formation.
  • Five main epitopes in FVIII (ar3, A2, A3, C1, C2 domains) are targeted by antibodies.

Conclusions:

  • FVIII gene mutation type is a critical determinant of inhibitor risk in severe hemophilia A.
  • The influence of patient genetics on inhibitor titer and epitope specificity in severe hemophilia A requires further elucidation.
  • Understanding these genetic links may inform personalized inhibitor risk assessment and management strategies.